Overview
- The action was formalized in Disposición 5866/2026 published in the Boletín Oficial, with the measure signed by ANMAT head Luis Eduardo Fontana.
- The cancellations follow an internal review by ANMAT’s Dirección de Gestión de Información Técnica that found 25 REM (Registro de Especialidades Medicinales) certificates with expiry dates between March 2019 and May 2025 and no reinscription process started.
- Fifteen firms are affected, with Lafedar and Laboratorio Internacional Argentino each losing five certificates and others including CSL Behring, Terumo BCT, Takeda and Megalabs listed in the annex.
- Notified companies cannot produce or market the listed specialties until they complete reinscription; they may file reconsideration or appeal within the administrative windows and have 180 days to start judicial action if they choose.
- ANMAT’s move comes alongside recent enforcement against unregistered CAFLAB products (Disposición 5970/2026) and cancellation of Royal Farma’s habilitaciones for a forged certificate (Disposición 6139/2026), showing stepped-up market checks that could affect short-term supply and procurement processes.